AJP - Gastrointestinal and Liver Physiology, Vol 263, Issue 5 642-G649, Copyright © 1992 by American Physiological Society

ARTICLES

Importance of the liver in plasma clearance of hepatocyte growth factors in rats

K. X. Liu, Y. Kato, M. Narukawa, D. C. Kim, M. Hanano, O. Higuchi, T. Nakamura and Y. Sugiyama
Faculty of Pharmaceutical Sciences, University of Tokyo, Japan.

After intravenous administration of 125I-labeled hepatocyte growth factor (HGF), trichloroacetic acid-precipitable radioactivity in the plasma disappeared rapidly with an early phase half-life of 4 min. The amounts of 125I-HGF distributed to the liver, adrenal, spleen, kidney, and lung tissues were much greater than those that could be accounted for by distribution to the extracellular space alone. The first-pass removal of 125I-HGF by the liver was approximately 26%; the liver accounted for approximately 70% of early-phase removal. The hepatic handling was also analyzed using a single-pass perfused liver system. The steady-state extraction ratio of tracer 125I-HGF was 0.48 but dropped to 0.23 in the presence of excess HGF (135 pM), demonstrating hepatic removal saturation of HGF. In the presence of excess HGF, the heparin-washable 125I-HGF, the heparin-resistant and acid-washable 125I-HGF, and the internalized 125I-HGF dropped to 54, 31, and 32% of the control values. The presence of at least two binding sites for HGF on the liver cell surfaces was made clear: the heparin-washable site and the heparin-resistant and acid-washable binding site, considered to have higher affinity for HGF. The internalization of 125I-HGF was observed to some extent even in the presence of excess HGF and phenylarsine oxide, known to be an inhibitor of polypeptides receptor-mediated endocytosis, suggesting the contribution of a relatively nonspecific internalization mechanism as well as receptor-mediated endocytosis.

This article has been cited by other articles:

				T. W. Hepburn, T. K. Hart, V. L. Horton, T. S. Sellers, L. P. Tobia, J. J. Urbanski, W. Shi, and C. B. Davis Pharmacokinetics and Tissue Distribution of SB-251353, a Novel Human CXC Chemokine, after Intravenous Administration to Mice J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 886 - 893. [Abstract] [Full Text]

				M. Kato, Y. Kato, T. Nakamura, and Y. Sugiyama Efficient Extraction by the Liver Governs Overall Elimination of Hepatocyte Growth Factor in Rats J. Pharmacol. Exp. Ther., July 1, 1999; 290(1): 373 - 379. [Abstract] [Full Text]

				M. Kato, Y. Kato, and Y. Sugiyama Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen Am J Physiol Endocrinol Metab, May 1, 1999; 276(5): E887 - E895. [Abstract] [Full Text] [PDF]

				K. Suzuki, H. Susaki, S. Okuno, H. Yamada, H. K. Watanabe, and Y. Sugiyama Specific Renal Delivery of Sugar-Modified Low-Molecular-Weight Peptides J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 888 - 897. [Abstract] [Full Text]

				M. Murata, I. Tamai, Y. Sai, O. Nagata, H. Kato, Y. Sugiyama, and A. Tsuji Hepatobiliary Transport Kinetics of HSR-903, a New Quinolone Antibacterial Agent Drug Metab. Dispos., November 1, 1998; 26(11): 1113 - 1119. [Abstract] [Full Text]

				K.-X. Liu, Y. Kato, I. Kino, T. Nakamura, and Y. Sugiyama Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats Am J Physiol Endocrinol Metab, November 1, 1998; 275(5): E835 - E842. [Abstract] [Full Text] [PDF]

				K.-X. Liu, Y. Kato, T.-I. Kaku, K. Matsumoto, T. Nakamura, and Y. Sugiyama Protamine enhances the proliferative activity of hepatocyte growth factor in rats Am J Physiol Gastrointest Liver Physiol, January 1, 1998; 274(1): G21 - G28. [Abstract] [Full Text] [PDF]

				M. Kato, H. Kamiyama, A. Okazaki, K. Kumaki, Y. Kato, and Y. Sugiyama Mechanism for the Nonlinear Pharmacokinetics of Erythropoietin in Rats J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 520 - 527. [Abstract] [Full Text]

				K.-X. Liu, Y. Kato, M. Kato, T.-I. Kaku, T. Nakamura, and Y. Sugiyama Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats Am J Physiol Endocrinol Metab, November 1, 1997; 273(5): E891 - E897. [Abstract] [Full Text] [PDF]

				M. Kato, K. Miura, H. Kamiyama, A. Okazaki, K. Kumaki, Y. Kato, and Y. Sugiyama Immunological Response to Repeated Administration of Recombinant Human Erythropoietin in Rats. Biphasic Effect on Its Pharmacokinetics Drug Metab. Dispos., September 1, 1997; 25(9): 1039 - 1044. [Abstract] [Full Text]

				O. Takenaka, T. Horie, H. Suzuki, and Y. Sugiyama Carrier-Mediated Active Transport of the Glucuronide and Sulfate of 6-Hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl) benzothiazole (E3040) into Rat Liver: Quantitative Comparison of Permeability in Isolated Hepatocytes, Perfused Liver and Liver in Vivo J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 948 - 958. [Abstract] [Full Text]